Andrew Michael Simmons

US Patent:

7179903, Feb 20, 2007

Filed:

Jul 6, 2004

Appl. No.:

10/885457

Inventors:

James G. McArthur - San Carlos CA, US
Dale John Talbot - San Francisco CA, US
Andrew D. Simmons - San Mateo CA, US
Ryan McGuinness - Oakland CA, US
Michael Kelly - Carlsbad CA, US
Lisa V. Tsui - Mountain View CA, US
Thomas Dull - San Francisco CA, US

Assignee:

Cell Genesys, Inc - South San Francisco CA

International Classification:

C07H 21/04
C12N 15/11
C12N 15/67
C12N 15/85
C12N 15/867

US Classification:

536 241, 4353201, 536 231

Abstract:

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

US Patent:

7632509, Dec 15, 2009

Filed:

Jul 18, 2006

Appl. No.:

11/488568

Inventors:

Jianmin Fang - Palo Alto CA, US
Karin Jooss - Bellevue WA, US
Andrew Simmons - San Mateo CA, US
Debbie Farson - San Francisco CA, US
Jing Jing Qian - Foster City CA, US

Assignee:

BioSante Pharmaceuticals, Inc. - Lincolnshire IL

International Classification:

A61K 39/21
A61K 39/38
A61K 39/295
C12N 7/00
C12N 7/02
C12N 15/00
C07K 16/00
A61K 39/395
A61K 39/275

US Classification:

4242071, 4241991, 4241841, 4242021, 4241301, 4353201, 4352351, 435239, 5303871

Abstract:

Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo.

US Patent:

7662623, Feb 16, 2010

Filed:

Oct 26, 2007

Appl. No.:

11/977787

Inventors:

Jianmin Fang - Foster City CA, US
Karin Jooss - Bellevue WA, US
Andrew Simmons - San Mateo CA, US
Jing-Jing Qian - Foster City CA, US

Assignee:

BioSante Pharmaceuticals, Inc. - Lincolnshire IL

International Classification:

C12N 15/00
C12N 15/11
C12N 15/13
C12P 21/08

US Classification:

4353201, 435 691, 536 231, 536 2353, 536 241, 536 242

Abstract:

Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.

US Patent:

7709224, May 4, 2010

Filed:

Apr 26, 2004

Appl. No.:

10/831304

Inventors:

Jianmin Fang - Foster City CA, US
Karin Jooss - Bellevue WA, US
Andrew Simmons - San Mateo CA, US
Jing-Jing Qian - Foster City CA, US

Assignee:

Biosante Pharmaceuticals, Inc. - Lincolnshire IL

International Classification:

C12P 21/00
C12P 21/08
C12N 15/10
C12N 15/11
C12N 7/00
C12N 15/13
C12N 5/10

US Classification:

435 691, 4353201, 435325, 435326, 536 241

Abstract:

Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.

US Patent:

7745179, Jun 29, 2010

Filed:

Jan 23, 2007

Appl. No.:

11/626192

Inventors:

James G. McArthur - San Carlos CA, US
Dale J. Talbot - San Francisco CA, US
Andrew D. Simmons - San Mateo CA, US
Ryan McGuinness - Oakland CA, US
Michael Kelly - Carlsbad CA, US
Lisa V. Tsui - Mountain View CA, US
Thomas Dull - San Francisco CA, US

Assignee:

GBP IP, LLC - Greenwich CT

International Classification:

C12N 15/64
C12N 15/00
C12P 21/06

US Classification:

435 914, 435 691, 4353201, 435455

Abstract:

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

US Patent:

7919079, Apr 5, 2011

Filed:

Mar 28, 2007

Appl. No.:

11/729339

Inventors:

Andrew Simmons - San Mateo CA, US
Karin Jooss - Bellevue WA, US
James Allison - New York NY, US

Assignee:

BioSante Pharmaceuticals, Inc. - Lincolnshire IL
The Regents of the University of California - Oakland CA

International Classification:

A01N 63/00

US Classification:

424 9321, 4242771

Abstract:

Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.

US Patent:

20030077812, Apr 24, 2003

Filed:

May 14, 2002

Appl. No.:

10/145289

Inventors:

James McArthur - San Carlos CA, US
Dale Talbot - San Francisco CA, US
Andrew Simmons - San Mateo CA, US
Ryan McGuinness - Oakland CA, US
Michael Kelly - Carlsbad CA, US
Lisa Tsui - Mountain View CA, US
Thomas Dull - San Francisco CA, US

International Classification:

C12N007/00
C12N005/08
C12N015/867

US Classification:

435/235100, 435/456000, 435/366000

Abstract:

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

US Patent:

20100317096, Dec 16, 2010

Filed:

Oct 26, 2007

Appl. No.:

11/977788

Inventors:

Jianmin Fang - Foster City CA, US
Karin Jooss - Bellevue WA, US
Andrew Simmons - San Mateo CA, US
Jing-Jing Qian - Foster City CA, US

Assignee:

Cell Genesys, Inc. - South San Francisco CA

International Classification:

C12N 15/63
C07H 21/04

US Classification:

4353201, 536 231

Abstract:

Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.